Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report)'s share price was up 6.7% during trading on Wednesday . The company traded as high as $3.47 and last traded at $3.29. Approximately 38,075 shares traded hands during mid-day trading, an increase of 71% from the average daily volume of 22,202 shares. The stock had previously closed at $3.08.
Analysts Set New Price Targets
Separately, UBS Group raised Nanobiotix to a "hold" rating in a research report on Monday, February 17th.
Read Our Latest Research Report on NBTX
Nanobiotix Stock Up 6.7 %
The stock's fifty day moving average price is $3.42 and its 200-day moving average price is $4.00.
Institutional Investors Weigh In On Nanobiotix
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. OLD Mission Capital LLC acquired a new stake in Nanobiotix in the fourth quarter valued at $139,000. Jane Street Group LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $73,000. Millennium Management LLC bought a new position in Nanobiotix during the fourth quarter worth about $39,000. Finally, Geode Capital Management LLC bought a new position in Nanobiotix during the fourth quarter worth about $29,000. 38.81% of the stock is owned by institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
